
Inogen (INGN) Stock Forecast & Price Target
Inogen (INGN) Analyst Ratings
Bulls say
Inogen Inc is strategically positioned for growth through its focus on enhancing synergies across sales channels and revitalizing its direct-to-consumer business, which could strengthen its competitive advantage in the portable oxygen concentrator market. The partnership with Yuwell for entry into the Chinese market presents significant long-term growth potential, capitalizing on a COPD market that is approximately ten times larger than that of the United States. Additionally, the projected growth of portable oxygen concentrators to comprise 58% of the market over the next five years further underscores the favorable outlook for Inogen's product demand.
Bears say
Inogen Inc. is facing significant challenges due to an oversized sales force that previously resulted in unprofitable operations, despite revenue growth. The company experienced marked revenue declines in both business-to-business (17%) and direct-to-consumer (28%) sales in 2023, indicating difficulties in its sales channel optimization efforts following new leadership in 4Q23. Additionally, shifts in patient reimbursement sources from higher-paying Medicare to lower-reimbursing private insurance and an increasing number of capped patients have further exacerbated revenue challenges, raising concerns about future financial stability.
This aggregate rating is based on analysts' research of Inogen and is not a guaranteed prediction by Public.com or investment advice.
Inogen (INGN) Analyst Forecast & Price Prediction
Start investing in Inogen (INGN)
Order type
Buy in
Order amount
Est. shares
0 shares